Graves’ Ophthalmopathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Graves' Ophthalmopathy – Pipeline Review, H2 2016’, provides an overview of the Graves' Ophthalmopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy

The report reviews pipeline therapeutics for Graves' Ophthalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Graves' Ophthalmopathy therapeutics and enlists all their major and minor projects

The report assesses Graves' Ophthalmopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Graves' Ophthalmopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Graves' Ophthalmopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Genmab A/S

Neothetics Inc

Novartis AG

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Graves' Ophthalmopathy Overview 6

Therapeutics Development 7

Pipeline Products for Graves' Ophthalmopathy - Overview 7

Graves' Ophthalmopathy - Therapeutics under Development by Companies 8

Graves' Ophthalmopathy - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Graves' Ophthalmopathy - Products under Development by Companies 11

Graves' Ophthalmopathy - Companies Involved in Therapeutics Development 12

Genmab A/S 12

Neothetics Inc 13

Novartis AG 14

Yuhan Corp 15

Graves' Ophthalmopathy - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Combination Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

(fluticasone propionate + salmeterol xinafoate) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

pasireotide ER - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Synthetic Peptides for Graves' Orbitopathy - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

teprotumumab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

YH-BIO - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

YH-NCE3 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Graves' Ophthalmopathy - Dormant Projects 36

Graves' Ophthalmopathy - Product Development Milestones 37

Featured News & Press Releases 37

Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 37

Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for Graves' Ophthalmopathy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Graves' Ophthalmopathy – Pipeline by Genmab A/S, H2 2016 12

Graves' Ophthalmopathy – Pipeline by Neothetics Inc, H2 2016 13

Graves' Ophthalmopathy – Pipeline by Novartis AG, H2 2016 14

Graves' Ophthalmopathy – Pipeline by Yuhan Corp, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Assessment by Combination Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Graves' Ophthalmopathy – Dormant Projects, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for Graves' Ophthalmopathy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports